Bionano Q1 revenue $6.7M (+4% YoY); gross margin 49%; positive coding updates

Bionano Genomics, Inc.

2026-Q1 EPS reported -$0.76 vs consensus -$0.97 ▲ beat (+21.6%)

Total revenue $6.7M (+4% vs $6.5M Q1 2025); consumables revenue $3.9M (+20%).
Gross margin improved to 49% from 46% YoY; sold 8,178 nanochannel flow cells (+17%).
Operating expenses cut 2% to $11.1M; adjusted op. expense +7% to $9.1M.
New CPT code 81354 for OGM in constitutional genetics effective Jan 1, 2026, priced above microarray codes.
Final CLFS shows 47% payment increase for CPT 81195 (OGM in hematologic malignancy) to $1,853.22.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bionano Genomics, Inc. reported first quarter ended March 31, 2026 results: revenue $6.7 million.

Period: first quarter ended March 31, 2026
Revenue: $6.7 million
Result: reported results

Exact text from the filing

towards growing our business.” Q1 2026 Financial Results For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $6.7 million, representing an increase of 4% from $6.5 million compared to the first quarter of 2025. • Consumables revenue was $3.9 million, representing an increase of 20% compared to the

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001411690-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.